Reported additional positive clinical data from the first two cohorts of patients with type 2 diabetes from ongoing Phase I/II study evaluating BMF-219.

Reported initial topline data from ongoing Phase I clinical trial showcasing initial responses in relapsed/refractory Acute Myeloid Leukemia (AML).

Continued enrolling four liquid tumor cohorts in ongoing Phase I study of BMF-219, and three KRAS-mutated solid tumors in ongoing Phase I study of BMF-219.

Continued advancing second product candidate, BMF-500, a novel third generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), toward the clinic; initiated a Phase I study of BMF-500.